{
    "Trade/Device Name(s)": [
        "Elecsys Testosterone II"
    ],
    "Submitter Information": "Roche Diagnostics",
    "510(k) Number": "K211685",
    "Predicate Device Reference 510(k) Number(s)": [
        "K093421"
    ],
    "Regulatory Class": "Class I, reserved",
    "Product Code(s)": [
        "CDZ"
    ],
    "Summary Letter Date": "February 4, 2022",
    "Summary Letter Received Date": "February 7, 2022",
    "Submission Date": "May 27, 2021",
    "Regulation Number(s)": [
        "21 CFR 862.1680"
    ],
    "Regulation Name(s)": [
        "Testosterone Test System"
    ],
    "Analyte Class(es)": [
        "chemistry",
        "endocrine"
    ],
    "Analyte(s)": [
        "Testosterone"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [
        "Li-heparin tube",
        "K2-EDTA tube",
        "K3-EDTA tube"
    ],
    "Instrument(s)/Platform(s)": [
        "cobas e 601 immunoassay analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Electrochemiluminescence immunoassay (ECLIA)",
        "Competitive immunoassay"
    ],
    "Methodologies": [
        "Electrochemiluminescence",
        "Competitive immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent",
        "Calibrator",
        "Control"
    ],
    "Document Summary": "FDA 510(k) summary for Elecsys Testosterone II immunoassay on cobas e 601 analyzer for quantitative determination of testosterone in serum and plasma",
    "Indications for Use Summary": "Quantitative immunoassay for testosterone in human serum and plasma to aid in diagnosis and treatment of disorders involving male sex hormones, including hypogonadism, delayed or precocious puberty, impotence in males, and hirsutism or virilization in females due to tumors, polycystic ovaries, and adrenogenital syndromes",
    "fda_folder": "Clinical Chemistry"
}